# LEMD3

## Overview
LEMD3 is a gene that encodes the LEM domain-containing protein 3, also known as MAN1, which is an integral component of the inner nuclear membrane. This protein is characterized by its nucleoplasmic N-terminal and C-terminal domains, along with two transmembrane segments, and is involved in crucial cellular signaling pathways. LEMD3 plays a significant role in modulating bone morphogenetic protein (BMP) and transforming growth factor beta (TGF-β) signaling by interacting with Smad proteins, thereby influencing bone development and homeostasis (Hellemans2004Lossoffunction). The protein's interactions with the barrier-to-autointegration factor (BAF) suggest its involvement in chromatin remodeling, transcription initiation, and DNA repair (Baasanjav2010Osteopoikilosis). Mutations in the LEMD3 gene are linked to several bone disorders, including osteopoikilosis, Buschke-Ollendorff syndrome, and melorheostosis, due to disrupted signaling pathways (Hellemans2004Lossoffunction).

## Structure
The LEMD3 protein, also known as MAN1, is an integral component of the inner nuclear membrane. It features a nucleoplasmic N-terminal and C-terminal domain, along with two transmembrane segments (Hellemans2004Lossoffunction). The N-terminal segment contains a conserved globular domain of approximately 40 amino acids, which is shared with other inner nuclear membrane proteins such as lamina-associated polypeptide 2 (LAP2) and emerin (Hellemans2004Lossoffunction). The C-terminal region of LEMD3 is crucial for its role in antagonizing BMP and TGFβ signaling pathways by binding to Smad proteins, specifically Smad1, Smad5, Smad8, and Smad2 (Hellemans2004Lossoffunction).

The LEMD3 protein is suggested to interact with the barrier-to-autointegration factor (BAF), a component of the chromatin remodeling complex, which is involved in transcription initiation and DNA repair (Baasanjav2010Osteopoikilosis). Mutations in the LEMD3 gene, such as nonsense and frameshift mutations, often result in truncated proteins lacking the Smad-interacting C-terminal domain, leading to a loss of function (Hellemans2004Lossoffunction). The protein's structure and function may also be influenced by post-translational modifications and splice variants, although specific details on these aspects are not provided in the context.

## Function
The LEMD3 gene encodes a protein that is integral to the inner nuclear membrane, playing a crucial role in regulating bone morphogenetic protein (BMP) and transforming growth factor beta (TGF-β) signaling pathways. These pathways are essential for bone development, differentiation of osteoblasts, and maintaining bone homeostasis (Frost2020Modelingbased; Hellemans2004Lossoffunction). LEMD3 interacts with Smad proteins, specifically binding to Smad1, Smad5, and Smad8 involved in BMP signaling, and Smad2 in the TGF-β pathway, thereby modulating these signaling cascades (Hellemans2004Lossoffunction).

In healthy human cells, LEMD3 functions to antagonize the activation of bone lining cells into bone-forming osteoblasts, thus regulating bone formation and remodeling processes. This regulation helps maintain a neutral remodeling balance at the basic multicellular unit (BMU) level, preventing excessive bone formation (Frost2020Modelingbased). Overexpression of LEMD3 has been shown to reduce the capacity of BMP4 to upregulate certain genes, indicating its inhibitory role in these pathways (Hellemans2004Lossoffunction).

LEMD3 is also involved in maintaining nuclear envelope integrity and is suggested to interact with the barrier-to-autointegration factor (BAF), which is essential for transcription initiation and DNA repair (Baasanjav2010Osteopoikilosis).

## Clinical Significance
Mutations in the LEMD3 gene are associated with several bone disorders, including osteopoikilosis, Buschke-Ollendorff syndrome (BOS), and melorheostosis. These conditions are characterized by abnormal bone growth and skin lesions due to disrupted BMP and TGF-beta signaling pathways (Hellemans2004Lossoffunction). Osteopoikilosis is an autosomal dominant skeletal dysplasia marked by multiple hyperostotic areas in the skeleton, while BOS is associated with osteopoikilosis and connective-tissue nevi (Hellemans2004Lossoffunction). Melorheostosis involves asymmetric hyperostosis of tubular bones and may include soft tissue abnormalities (Hellemans2004Lossoffunction).

LEMD3 mutations result in loss of function, often due to exon skipping, frameshifts, and premature stop codons, leading to truncated proteins lacking the Smad-interacting C-terminal domain (Hellemans2004Lossoffunction). This loss of function enhances TGF-beta signaling, contributing to the development of these disorders (Hellemans2004Lossoffunction). In some cases, LEMD3 mutations may interact with other genetic factors, influencing the presentation of the disease (Baasanjav2010Osteopoikilosis). While LEMD3 mutations are linked to osteopoikilosis and BOS, they are not a major cause of isolated melorheostosis, which may instead be associated with mosaic mutations in other genes (Gnoli2019Melorheostosis).

## Interactions
LEMD3, also known as MAN1, is a protein that plays a significant role in cellular signaling pathways by interacting with various proteins. It is an integral component of the inner nuclear membrane and contains a nucleoplasmic N-and C-terminal domain along with two transmembrane segments. The C-terminal region of LEMD3 is crucial for its function, as it binds to Smad proteins, specifically Smad1, Smad5, and Smad8, to antagonize BMP signaling. This interaction is essential for regulating bone development and is implicated in conditions such as osteopoikilosis, Buschke-Ollendorff syndrome, and melorheostosis (Hellemans2004Lossoffunction).

LEMD3 also interacts with the MH2 domains of Smad1 and Smad2, indicating its involvement in both BMP and TGF-beta signaling pathways (Hellemans2004Lossoffunction). The protein's interaction with Smad proteins is vital for its role in these pathways, as demonstrated by yeast two-hybrid analysis and luciferase assays (Hellemans2004Lossoffunction).

Additionally, LEMD3 is suggested to interact with the barrier-to-autointegration factor (BAF), a component of the chromatin remodeling complex, which is important for transcription initiation and may regulate the expression of osteogenic genes (Baasanjav2010Osteopoikilosis). These interactions highlight LEMD3's multifaceted role in cellular processes and its impact on bone density disorders.


## References


[1. (Gnoli2019Melorheostosis) Maria Gnoli, Eric Lodewijk Staals, Laura Campanacci, Maria Francesca Bedeschi, Flavio Faletra, Salvatore Gallone, Agostino Gaudio, Teresa Mattina, Fiorella Gurrieri, Antonio Percesepe, Iria Neri, Annalucia Virdi, Morena Tremosini, Annamaria Milanesi, Evelise Brizola, Elena Pedrini, and Luca Sangiorgi. Melorheostosis and osteopoikilosis clinical and molecular description of an italian case series. Calcified Tissue International, 105(2):215–221, May 2019. URL: http://dx.doi.org/10.1007/s00223-019-00565-6, doi:10.1007/s00223-019-00565-6. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00223-019-00565-6)

[2. (Frost2020Modelingbased) M. Frost, E.T. Rahbek, C. Ejersted, P.F. Høilund-Carlsen, A. Bygum, J.S. Thomsen, C.M. Andreasen, T.L. Andersen, and A.L. Frederiksen. Modeling-based bone formation transforms trabeculae to cortical bone in the sclerotic areas in buschke-ollendorff syndrome. a case study of two females with lemd3 variants. Bone, 135:115313, June 2020. URL: http://dx.doi.org/10.1016/j.bone.2020.115313, doi:10.1016/j.bone.2020.115313. This article has 6 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bone.2020.115313)

[3. (Baasanjav2010Osteopoikilosis) Sevjidmaa Baasanjav, Aleksander Jamsheer, Mateusz Kolanczyk, Denise Horn, Tomasz Latos, Katrin Hoffmann, Anna Latos-Bielenska, and Stefan Mundlos. Osteopoikilosis and multiple exostoses caused by novel mutations in lemd3 and ext1 genes respectively - coincidence within one family. BMC Medical Genetics, July 2010. URL: http://dx.doi.org/10.1186/1471-2350-11-110, doi:10.1186/1471-2350-11-110. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2350-11-110)

[4. (Hellemans2004Lossoffunction) Jan Hellemans, Olena Preobrazhenska, Andy Willaert, Philippe Debeer, Peter C M Verdonk, Teresa Costa, Katrien Janssens, Bjorn Menten, Nadine Van Roy, Stefan J T Vermeulen, Ravi Savarirayan, Wim Van Hul, Filip Vanhoenacker, Danny Huylebroeck, Anne De Paepe, Jean-Marie Naeyaert, Jo Vandesompele, Frank Speleman, Kristin Verschueren, Paul J Coucke, and Geert R Mortier. Loss-of-function mutations in lemd3 result in osteopoikilosis, buschke-ollendorff syndrome and melorheostosis. Nature Genetics, 36(11):1213–1218, October 2004. URL: http://dx.doi.org/10.1038/ng1453, doi:10.1038/ng1453. This article has 353 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ng1453)